Key result
Lifelong oral treatment with ranolazine prevented the development of morphological and functional cardiac phenotype in 12-month-old male mice carrying an HCM-related mutation.
Why the study?
Does ranolazine prevent the development of morphological and functional cardiac phenotype in a mouse model of hypertrophic cardiomyopathy?
Does ranolazine prevent the development of morphological and functional cardiac phenotype in a mouse model of hypertrophic cardiomyopathy?
Lifelong oral ranolazine prevented the development of morphological and functional cardiac phenotype in a mouse model of hypertrophic cardiomyopathy, suggesting potential as an early preventive therapy.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use in HCM; leaves open disease-modifying potential in genetic models.
Coppini et al. (2017) studied Hypertrophic cardiomyopathy. Ranolazine vs. vehicle was evaluated on development of HCM-related cardiac phenotype. Lifelong oral treatment with ranolazine prevented the development of morphological and functional cardiac phenotype in 12-month-old male mice carrying an HCM-related mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: